USPTO Patent Applications - Pharma (A61K)

USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections

The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.

USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells

The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.

USPTO Patent Application: Dapiprazole for Eye Disorders

The USPTO has published a patent application (US20260083730A1) for a method of treating eye disorders using dapiprazole. The application, filed by Baradaina LLC, details a liquid composition for treating conditions such as presbyopia, glaucoma, or halos and glare.

Uveal Melanoma Treatment Patent Application

The USPTO has published a patent application (US20260083731A1) detailing methods for treating uveal melanoma using a PKC inhibitor. The application, filed on August 25, 2023, by inventors Matthew Anthony Maurer, Michael Gabriel O'Quigley, and Julie Hambleton, focuses on neoadjuvant and/or adjuvant therapy to reduce metastasis and preserve eye function.

USPTO Patent Application: Upadacitinib Pharmaceutical Composition

The USPTO has published a new patent application (US20260083732A1) detailing a pharmaceutical composition for upadacitinib. The application, filed on September 6, 2023, describes a formulation involving upadacitinib, a hydrophobic release-controlling polymer, a pH modifier, and other excipients.

USPTO Patent Application: TYK2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.

USPTO Patent Application for Tyk2 Inhibitor Dosage Forms

The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.

USPTO Patent Application for ABHD6 Antagonist Drug

The USPTO has published a patent application filed by ONO Pharmaceutical Co., Ltd. for a novel ABHD6 antagonist drug. The application details a compound with potential therapeutic applications for diseases associated with ABHD6 activity.

USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder

The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.

USPTO Patent Application: Modified Release Minoxidil Formulations

The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.

USPTO Patent Application: Modified Release Minoxidil for Hair Loss

The USPTO has published a patent application (US20260083738A1) detailing modified release minoxidil oral formulations for treating hair loss. The application, filed by Reid Waldman, describes compositions including minoxidil alone or with other active agents, and methods of treatment. This represents a new patent filing for a potential pharmaceutical product.

USPTO Patent Application: Dietary Compositions for Health and Diabetes Treatment

The USPTO has published a patent application (US20260083739A1) for dietary compositions containing minerals and vitamins, intended for various health benefits including diabetes treatment, improved athletic performance, and immune support. The application was filed on December 2, 2025.

USPTO Patent Application for Tavapadon in Parkinson's Disease Treatment

The USPTO has published a patent application (US20260083740A1) detailing methods for treating Parkinson's Disease using escalating doses of tavapadon. The application was filed on September 23, 2025, by inventor Sridhar Duvvuri.

Sotorasib Dosing Regimen Patent Application

The USPTO has received a patent application (US20260083741A1) for a sotorasib dosing regimen. The application, filed by Brett E. Houk and Panli Cardona, details methods for administering sotorasib to patients, particularly those with KRAS G12C-mutated cancer who also require treatment with a BCRP substrate like rosuvastatin.

Patent Application for Cancer Treatment with Azenosertib and HRD Biomarker

The USPTO has published a patent application (US20260083742A1) detailing methods for treating cancer by administering azenosertib to subjects selected based on homologous recombination repair deficiency (HRD). The application was filed on December 1, 2025.

USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment

The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.

USPTO Patent Application for Visual Pathway Strengthening Methods

The USPTO has published a new patent application (US20260083744A1) for methods of treating visual impairment by strengthening visual pathways. The application was filed on September 26, 2025, by inventors Ming-Fai Fong and Robert D. Lamprecht.

Reduced Dosing Regimens for Glaucoma Treatment Methods

The USPTO has published a patent application (US20260083746A1) detailing methods for treating open-angle glaucoma by transitioning patients to a once-daily dosing regimen. The proposed treatment involves a pharmaceutical composition containing timolol, brimonidine, dorzolamide, and bimatoprost.

USPTO Patent Application: Compositions for Mitochondrial Health

The USPTO has published a patent application (US20260083747A1) detailing compositions for supporting mitochondrial health using methylthioninium salts combined with other compounds. The application was filed on October 30, 2024, by inventors Darren Lopez and Dan Schmidt.

USPTO Patent for Anti-CD123 Immunoconjugates Treating AML

The USPTO has published a patent application (US20260083749A1) for anti-CD123 immunoconjugates, such as pivekimab sunirine, for treating acute myeloid leukemia (AML). The patent covers methods of use as monotherapies or in combination with other agents to achieve remission or prepare patients for transplant.

USPTO Patent Application: Small Molecule Inhibitors of KRAS Proteins for Cancer Treatment

The USPTO has published a patent application (US20260083750A1) detailing small molecule inhibitors of KRAS proteins for cancer treatment. The application describes compounds that can inhibit specific KRAS protein mutants and their potential utility as therapeutic agents for cancer.

USPTO Patent Application: Allosteric Modulators for CRPC Therapy

The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.

Patent Application: Cancer Treatment Methods and Compositions

The USPTO has published a patent application (US20260083752A1) for methods and compositions for treating cancer. The application, filed by the Regents of the University of Minnesota, involves the combination of p300/CBP modulators with senotherapeutics.

USPTO Patent Application for Metabolic Syndrome Treatment

The USPTO has published a patent application (US20260083753A1) for compositions and methods to treat metabolic syndrome. The application, filed by Kotha Sekharam, details improved compositions with enhanced solubility and bioavailability.

USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation

The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.

Testosterone Composition for Oral Delivery Treats Hypogonadism

The USPTO has published a patent application (US20260083755A1) assigned to NEUROCRINE UK LIMITED for a testosterone-containing pharmaceutical composition adapted for oral delivery. The application details treatment regimens and methods for hormone-related conditions like hypogonadism in human subjects.

USPTO Patent Application: Cannabinoid Delivery Capsules

The USPTO has published a new patent application (US20260083756A1) from Fertin Pharma A/S for capsules designed for peroral cannabinoid delivery. The application details formulations using self-emulsifying drug delivery systems (SEDDS) with specific surfactant and cannabinoid content.

USPTO Patent Application for Self-Emulsifying Drug Delivery Systems

The USPTO has published a patent application from Fertin Pharma A/S for a dosage form utilizing self-emulsifying drug delivery systems (SEDDS) for cannabinoids. The application details specific formulations including surfactants with PEG moieties and isolated or synthetic cannabinoids.

USPTO Patent Application: Psychedelics Combined with NMDA Receptor Agonists

The USPTO has published a patent application (US20260083759A1) detailing combinations of psychedelic drugs with NMDA receptor agonists for treating neuropsychiatric and neurologic disorders. The application was filed on August 29, 2023, and is scheduled for publication on March 26, 2026.

USPTO Patent Application: Stable Liquid Bortezomib Formulations

The USPTO has published a patent application (US20260083760A1) for stable liquid bortezomib formulations filed by Riconpharma LLC. The application describes liquid compositions with specific impurity limits for intravenous or subcutaneous use.

USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment

The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.

USPTO Patent Application: Sialic Acid Compositions for Coronavirus Infections

The USPTO has published a patent application (US20260083762A1) detailing compositions comprising sialic acid for inhibiting or treating coronavirus infections, specifically those caused by SARS-CoV-2. The application was filed on August 18, 2025, by inventor Jan Remmereit.

USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases

The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.

USPTO Patent Application for NAD+ Concentration Support Compositions

The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.

USPTO Patent Application: Neurodegenerative Disorder Treatment

The USPTO has published a new patent application (US20260083766A1) detailing methods for treating neurodegenerative disorders by modulating RNA editing. The application was filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli.

USPTO Patent Application: Solid Dosage Form of Antiviral Nucleoside

The USPTO has published a new patent application from Merck Sharp & Dohme LLC for an oral dosage form of a small molecule antiviral nucleoside. The application details specific formulation components and pellet size requirements for the antiviral drug.

USPTO Patent Application: Inflammasome Inhibition for Neuroprotection

The USPTO has published a new patent application detailing methods for treating retinal detachment using inflammasome inhibition. The application, filed by Jayakrishna Ambati, Peirong Huang, and Kameshwari Ambati, focuses on improving visual outcomes for patients with rhegmatogenous retinal detachment.

USPTO Patent Application: RNA Complexes for Cancer Metastasis Treatment

The USPTO has published a new patent application detailing RNA complexes and nanostructures for cancer metastasis treatment. The application describes a one-step CMC production method for RNA therapeutic complexes containing nucleoside analogues, which self-assemble during RNA synthesis.

USPTO Patent Application: Method for Forming Drops Dispersion

The USPTO has published a patent application detailing a method for forming a dispersion with fatty and aqueous phases, including specific steps for creating and conveying fatty phase drops. This application, filed by inventors Duncan Gilbert and Mathieu Goutayer, outlines a novel approach to dispersion formation for potential use in various product formulations.

USPTO Patent Application: Topical Delivery Systems

The USPTO has published a new patent application (US20260083647A1) detailing topical delivery systems and multi-phase formulations. The application describes sustained-release barrier formulations designed for skin application, potentially offering time-dependent effects like hair follicle softening and delayed active ingredient delivery.

USPTO Patent Application: Deodorant Compositions

The USPTO has published a patent application (US20260083648A1) for deodorant compositions described by Dr. Squatch, LLC. The application details specific ingredient percentages for stick deodorants, emphasizing a high percentage of natural or naturally-derived ingredients.

USPTO Patent Application: Oral Care Composition with Mint Oil and Tin

The USPTO has published a new patent application (US20260083649A1) for an oral care composition. The invention involves a blend of mint oil, tin, and flavor extract designed to prevent the formation of methyl mercaptan, a compound that can cause unpleasant odors.

USPTO Patent Application: Oral Care Compositions

The USPTO has published a new patent application from Colgate-Palmolive Company for oral care compositions containing amino acids and flavor components. The application details methods of making and using these stabilized compositions, aiming to combine traditionally incompatible ingredients.

USPTO Patent Application for Skin Care Formulations

The USPTO has published a patent application (US20260083651A1) for skin care formulations. The application details a method of treating skin and a topical composition including various extracts and active ingredients. The filing date for this application was December 4, 2025.

USPTO Patent Application for Renewable Ester Emollient

The USPTO has published a patent application (US20260083652A1) for a renewable ester emollient for enhanced cutaneous permeation, assigned to Oxiteno S.A. Indústria e Comércio. The application details a personal care formulation and a method for moisturizing skin or hair using this emollient.

USPTO Patent Application: Tooth Whitening Preparation System

The USPTO has published a patent application (US20260083653A1) for a tooth whitening preparation system and method filed by Cobea AG. The application describes a component system including an active ingredient component and an activation component designed to adjust the pH for a physiologically acceptable tooth whitening preparation.

USPTO Patent Application for Photoprotective System

The USPTO has published a patent application (US20260083654A1) for a photoprotective system consisting of four specific sunscreens, assigned to PIERRE FABRE DERMO-COSMETIQUE. The application details a cosmetic or pharmaceutical composition with a photoprotective system representing 4% to 20% by weight.

USPTO Patent Application: Sjögren's Syndrome Detection and Treatment

The USPTO has published a patent application detailing methods for detecting and treating Sjögren's syndrome using salivary exosomes. The application, filed by inventors from various institutions, outlines novel diagnostic and therapeutic approaches for the autoimmune disease.

USPTO Patent Application: Pyramidal Meditation Structure Device

The USPTO has published a patent application for a pyramidal meditation structure device. The application, filed by Rein Daloul, describes a structure with vertical beams, walls, an entrance, and integrated pipes with crystals intended to impart healing energy during meditation.

USPTO Patent Application: T cell isolation methods

The USPTO has published patent application US20260079159A1 detailing methods for isolating and expanding specific types of T cells (CD127lo/− regulatory T cells) for potential use in treating immune system disorders. The application was filed on September 12, 2025.